References
- Hazin R, Abuzetun JY, Daoud YJ, Abu-Khalaf MM. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. Curr Opin Ophthalmol 2009;20:308-317. https://doi.org/10.1097/ICU.0b013e32832c9007
- Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist 2004;9:482-488. https://doi.org/10.1634/theoncologist.9-5-482
- Esmaeli B, Burnstine MA, Ahmadi MA, Prieto VG. Docetaxel-induced histologic changes in the lacrimal sac and the nasal mucosa. Ophthal Plast Reconstr Surg 2003;19:305-308. https://doi.org/10.1097/01.IOP.0000075016.29682.E0
- Gowda A, Goel R, Berdzik J, Leichman CG, Javle M. Hypersensitivity reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 2004;18:1671-1675.
- Eguia B, Ruppert AM, Fillon J, et al. Skin toxicities compromise prolonged pemetrexed treatment. J Thorac Oncol 2011;6:2083-2089. https://doi.org/10.1097/JTO.0b013e31822e722f
Cited by
- Pemetrexed : Epiphora secondary to lacrimal punctal and canaliculi stenosis: case report vol.1676, pp.1, 2017, https://doi.org/10.1007/s40278-017-38225-8